<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675528</url>
  </required_header>
  <id_info>
    <org_study_id>107CS-7</org_study_id>
    <nct_id>NCT04675528</nct_id>
  </id_info>
  <brief_title>Food Effect on Pharmacokinetics and SafEty of DHP107 (Liporaxel®) FEEL Study</brief_title>
  <acronym>FEEL</acronym>
  <official_title>A Randomized, Open-label, Two-way Crossover Clinical Trial to Evaluate the Food Effect on Pharmacokinetics and Safety of DHP107 (Oral Paclitaxel, Liporaxel®) in Patients With Advanced Solid Tumors (FEEL) / EudraCT no : 2020-004976-16</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daehwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daehwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the food effect on pharmacokinetics of DHP107 in patients with advanced solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, open-label, two-way crossover study consisting of two sequences (RT, TR) in patients with advanced solid tumor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Cmax</measure>
    <time_frame>Day 1 and Day 8 of Cycle 1(each cycle is 28 days)</time_frame>
    <description>The primary endpoints of this trial are the ratio of geometric means of the following pharmacokinetic parameters following DHP107 administration fed with fasting condition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>• Tmax</measure>
    <time_frame>Day 1 and Day 8 of Cycle 1(each cycle is 28 days)</time_frame>
    <description>and the median difference of the following pharmacokinetic parameters following DHP107 administration fed with fasting condition:</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Fasting treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHP107(Oral paclitaxel)</intervention_name>
    <description>DHP107 200 mg/m2 orally twice daily on Days 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m2 orally once daily on Days 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)</description>
    <arm_group_label>Fasting treatment</arm_group_label>
    <arm_group_label>Fed treatment</arm_group_label>
    <other_name>Liporaxel®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are ≥18 years of age on the date of written informed consent.&#xD;
&#xD;
          2. Subjects with histologically or cytologically confirmed advanced solid tumors&#xD;
             including but not limited to the listed below for which paclitaxel monotherapy has&#xD;
             been determined an appropriate therapy at the investigator's discretion.&#xD;
&#xD;
               -  Angiosarcoma&#xD;
&#xD;
               -  Bladder cancer&#xD;
&#xD;
               -  Breast cancer&#xD;
&#xD;
               -  Cervical cancer&#xD;
&#xD;
               -  Head and neck cancer (if no difficulty with swallowing)&#xD;
&#xD;
               -  Kaposi's sarcoma&#xD;
&#xD;
               -  Lung cancer&#xD;
&#xD;
               -  Ovarian cancer&#xD;
&#xD;
          3. Subjects who have a life expectancy of ≥12 weeks.&#xD;
&#xD;
          4. Subjects who are able to take oral medication.&#xD;
&#xD;
          5. Subjects who have a performance status of ≤ 2 on the Eastern Cooperative Oncology&#xD;
             Group (ECOG) scale.&#xD;
&#xD;
          6. Subjects who have evaluable disease according to the Response Evaluation Criteria in&#xD;
             Solid Tumors Version 1.1 (RECIST version 1.1).&#xD;
&#xD;
          7. Subjects who have adequate organ functions as indicated by the following laboratory&#xD;
             values:&#xD;
&#xD;
          8. Subjects who are willing and able to comply with scheduled visits, treatment plans,&#xD;
             laboratory tests, and procedures.&#xD;
&#xD;
          9. Subjects who have voluntarily agreed to participate by giving written informed&#xD;
             consent.&#xD;
&#xD;
         10. Women of childbearing potential who have negative pregnancy test results at the&#xD;
             screening visit and men with female partners of childbearing potential must agree to&#xD;
             use adequate contraception for the duration of the trial and up to 90 days after last&#xD;
             dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have history of severe hypersensitive reaction to the active ingredient&#xD;
             or any excipients of DHP107.&#xD;
&#xD;
          2. Subjects with following surgical history/medical conditions that may affect drug&#xD;
             absorption:&#xD;
&#xD;
          3. Subjects who developed cardiovascular disease (unstable angina, myocardial infarction,&#xD;
             stroke, and transient ischemic attack) within 24 weeks prior to study entry, which is&#xD;
             deemed to be clinically significant by the investigator.&#xD;
&#xD;
          4. Subjects with known active hepatitis B or C infection, or hepatobiliary disease, or&#xD;
             known history of immunodeficiency virus infection (However, subjects with Gilbert's&#xD;
             Syndrome, asymptomatic gallstones, or stable chronic liver disease are, at the&#xD;
             discretion of the investigator, eligible for the study. Subjects who are hepatitis B&#xD;
             carriers may be eligible if they are on antiviral therapy 2 weeks prior to study&#xD;
             entry).&#xD;
&#xD;
          5. Subjects with neuropathy grade &gt; 2 based on CTCAE v5.0 at the time of study entry.&#xD;
&#xD;
          6. Subjects with uncontrolled medical or mental illness that, in the investigator's&#xD;
             judgement, could affect treatment tolerability or compliance.&#xD;
&#xD;
          7. Subjects diagnosed with other malignant primary tumor with an exception of the&#xD;
             following:&#xD;
&#xD;
               -  Malignancy diagnosed at least 5 years previously without evidence of recurrence&#xD;
                  or persistent disease&#xD;
&#xD;
               -  The complete excision of basal/squamous cell carcinoma or papillary thyroid&#xD;
                  carcinoma or the complete treatment of cervical intraepithelial neoplasia or&#xD;
                  other in situ carcinoma&#xD;
&#xD;
          8. Subjects with symptomatic or unstable, untreated metastases to the central nervous&#xD;
             system (CNS) at the time of screening ('Unstable' means worsening of symptoms within 4&#xD;
             weeks prior to screening).&#xD;
&#xD;
          9. Subjects who are currently receiving alternative cytotoxic agents, regular systemic&#xD;
             corticosteroids and medications that could influence drug absorption (e.g.&#xD;
             H2-antihistamines, antacids, metoclopramide and charcoal) within 4 weeks prior to&#xD;
             entry into the study (C1D1).&#xD;
&#xD;
         10. Subjects who are currently receiving (or unable to stop use the 3 days before the&#xD;
             first dose of DHP107 and throughout the study) prescription or non-prescription&#xD;
             medications or other products known to be moderate or potent inhibitors/inducers of&#xD;
             CYP3A4, P-gp, or CYP2C8.&#xD;
&#xD;
         11. Subjects who cannot intake whole high fat meal offered.&#xD;
&#xD;
         12. Pregnant or breastfeeding women.&#xD;
&#xD;
         13. Subjects who have received any investigational drugs or devices within 4 weeks before&#xD;
             the first day of study treatment (C1D1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erika Hitre, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erika Hitre, M.D., Ph.D</last_name>
    <phone>+36-1-22-48-763</phone>
    <email>hitre@oncol.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Semmelweis, 1st Internal Medicine Clinic, Department of Clinical Pharmacology</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <contact>
      <last_name>István TAKÁCS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <contact>
      <last_name>Erika Hitre, M.D., Ph.D</last_name>
      <phone>+36-1-22-48-763</phone>
      <email>hitre@oncol.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Debrecen-Clinical Center, Internal Medicine Clinic, Department of Clinical Pharmacology</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <contact>
      <last_name>Dénes PÁLL</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Liporaxel</keyword>
  <keyword>DHP107</keyword>
  <keyword>Oral paclitaxel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

